Mitochondrial medicine for neurodegenerative diseases
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Mitochondrial dysfunction has been reported in a wide array of neurological disorders ranging from neuromuscular to neurodegenerative diseases. Recent studies on neurodegenerative diseases have revealed that mitochondrial pathology is generally found in inherited or sporadic neurodegenerative diseases and is believed to be involved in the pathophysiological process of these diseases. Commonly seen types of mitochondrial dysfunction in neurodegenerative diseases include excessive free radical generation, lowered ATP production, mitochondrial permeability transition, mitochondrial DNA lesions, perturbed mitochondrial dynamics and apoptosis. Mitochondrial medicine as an emerging therapeutic strategy targeted to mitochondrial dysfunction in neurodegenerative diseases has been proven to be of value, though this area of research is still at in its early stage. In this article, we report on recent progress in the development of several mitochondrial therapies including antioxidants, blockade of mitochondrial permeability transition, and mitochondrial gene therapy as evidence that mitochondrial medicine has promise in the treatment of neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality
Miller, E. R., Pastor-Barriuso, R., Dalal, D., Riemersma, R. A., Appel, L. J., & Guallar, E. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-1-200501040-00110 · Cited by 2,577 · cited 1×
“In addition, high dosage of Vit E supplementation (>150 IU/day) may increase the mortality of receivers (Miller et al., 2005).”
BackgroundCalcium, ATP, and ROS: a mitochondrial love-hate triangle
Brookes, P. S., Yoon, Y., Robotham, J. L., Anders, M. W., & Sheu, S.-S. (2004) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00139.2004 · Cited by 2,575
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380 · cited 1×
“Daily doses of 2000 IU Vit E has been observed to be beneficial to mild-to-moderate stage AD patients (Petersen et al., 2005; Sano et al., 1997).”
BackgroundBaines, C. P., Kaiser, R. A., Purcell, N. H., Blair, N. S., Osinska, H., Hambleton, M. A., Brunskill, E. W., Sayen, M. R., Gottlieb, R. A., Dorn, G. W., et al. (2005) · Nature · doi:10.1038/nature03434 · Cited by 2,280
Mitochondria: Dynamic Organelles in Disease, Aging, and Development
Chan, D. C. (2006) · Cell · doi:10.1016/j.cell.2006.06.010 · Cited by 1,987 · cited 3×
“The regulation of mitochondrial dynamics requires a delicate balance of fusion and fission proteins (Chan, 2006).”
BackgroundVitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844 · cited 1×
“Daily doses of 2000 IU Vit E has been observed to be beneficial to mild-to-moderate stage AD patients (Petersen et al., 2005; Sano et al., 1997).”
BackgroundThe importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses
Li, Z., Okamoto, K.-I., Hayashi, Y., & Sheng, M. (2004) · Cell · doi:10.1016/j.cell.2004.11.003 · Cited by 1,498 · cited 2×
“Neuronal mitochondrial function and behavior in normal fashion are the endorsement of the high energy demanding synaptic activity by rapidly providing energy (Onyango et al., 2010; Mattson, 2007; Hollenbeck and Saxton, 2005; Li et al., 2004) and modulating calcium kinetics and metabolism in the strategic neuronal comp…”
BackgroundABAD Directly Links Aß to Mitochondrial Toxicity in Alzheimer's Disease
Lustbader, J. W., Cirilli, M., Lin, C., Xu, H. W., Takuma, K., Wang, N., Caspersen, C., Chen, X., Pollak, S., Chaney, M., et al. (2004) · Science · doi:10.1126/science.1091230 · Cited by 1,303
Self-citationGeneration of reactive oxygen species by the mitochondrial electron transport chain
Liu, Y., Fiskum, G., & Schubert, D. (2002) · Journal of Neurochemistry · doi:10.1046/j.0022-3042.2002.00744.x · Cited by 1,260 · cited 2×
“Furthermore, mitochondrial complexes I and III are known major mitochondrial free radical producing sites, whereas damaged complexes II and IV activities will also lead to burst of reactive oxygen species (ROS) generation in pathological conditions (Liu et al., 2002; Grivennikova and Vinogradov, 2006; Muller et al., 2…”
BackgroundImpaired Balance of Mitochondrial Fission and Fusion in Alzheimer's Disease
Wang, X., Su, B., Lee, H.-G., Li, X., Perry, G., Smith, M. A., & Zhu, X. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1357-09.2009 · Cited by 1,224
S-Nitrosylation of Drp1 Mediates β-Amyloid-Related Mitochondrial Fission and Neuronal Injury
Cho, D.-H., Nakamura, T., Fang, J., Cieplak, P., Godzik, A., Gu, Z., & Lipton, S. A. (2009) · Science · doi:10.1126/science.1171091 · Cited by 1,092
Complex iii releases superoxide to both sides of the inner mitochondrial membrane
Muller, F. L., Liu, Y., & Van Remmen, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407715200 · Cited by 1,036
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984 · cited 1×
“For example, coenzyme Q10 (CoQ10) and vitamin E (Vit E) have been shown to be effective in clinical trials, showing the promise of mitochondrial medicine applications for the treatment of neurodegenerative disease (Kasparova et al., 2006; Shults et al., 2002; Pham and Plakogiannis, 2005).”
BackgroundReddy, P. H., & Beal, M. F. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.002 · Cited by 975
Mitochondria take center stage in aging and neurodegeneration
Beal, M. F. (2005) · Annals of Neurology · doi:10.1002/ana.20624 · Cited by 957
The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it
Fahn, S., & Cohen, G. (1992) · Annals of Neurology · doi:10.1002/ana.410320616 · Cited by 927 · cited 1×
“The combination of Vit E and Vit C has been reported to delay the progression of PD (Fahn, 1992; Fahn and Cohen, 1992).”
BackgroundWang, X., Su, B., Siedlak, S. L., Moreira, P. I., Fujioka, H., Wang, Y., Casadesus, G., & Zhu, X. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804871105 · Cited by 835
Allan Butterfield, D. (2002) · Free Radical Research · doi:10.1080/1071576021000049890 · Cited by 786
The axonal transport of mitochondria
Hollenbeck, P. J., & Saxton, W. M. (2005) · Journal of Cell Science · doi:10.1242/jcs.02745 · Cited by 771
Mitochondrial defect in Huntington's disease caudate nucleus
Gu, M., Gash, M. T., Mann, V. M., Javoy‐Agid, F., Cooper, J. M., & Schapira, A. H. V. (1996) · Annals of Neurology · doi:10.1002/ana.410390317 · Cited by 758 · cited 2×
“Symptomatic HD patients demonstrate decreased complex II activity in caudate and putamen (Benchoua et al., 2006; Browne, 2008; Calabresi et al., 2001; Gu et al., 1996) with decreased expression of the complex II iron–sulfur subunit in caudate and putamen tissues from HD patients (Benchoua et al.”
BackgroundRezai-Zadeh, K., Shytle, D., Sun, N., Mori, T., Hou, H., Jeanniton, D., Ehrhart, J., Townsend, K., Zeng, J., Morgan, D., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1521-05.2005 · Cited by 713
Gandhi, S., Wood-Kaczmar, A., Yao, Z., Plun-Favreau, H., Deas, E., Klupsch, K., Downward, J., Latchman, D. S., Tabrizi, S. J., Wood, N. W., et al. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.02.013 · Cited by 682
Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury
Adlam, V. J., Harrison, J. C., Porteous, C. M., James, A. M., Smith, R. A. J., Murphy, M. P., & Sammut, I. A. (2005) · The FASEB Journal · doi:10.1096/fj.05-3718com · Cited by 618 · cited 1×
“Lipophilic cations have been proved to be effective to facilitate molecular transport across the hydrophobic barrier of the lipid bilayers (Murphy, 2008; Adlam et al., 2005).”
BackgroundMatthews, R. T., Yang, L., Browne, S., Baik, M., & Beal, M. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8892 · Cited by 557 · cited 1×
“Importantly, clinical trials for CoQ10 administration to treat PD, HD and ALS have been resulted in positive data regarding neuroprotection (Matthews et al., 1998; Beal et al., 1998; Int J Biochem Cell Biol.”
BackgroundCoskun, P. E., Beal, M. F., & Wallace, D. C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403649101 · Cited by 556 · cited 1×
“Abnormally high levels of mtDNA lesions are a hallmark in many neurodegenerative diseases, including AD, PD, HD, ALS and Friedrich’s ataxia (Coskun et al., 2004; Hutchin et al., 1997; Wiedemann et al., 2002; Polidori et al., 1999).”
BackgroundBrain cytochrome oxidase in Alzheimer's disease
Kish, S. J., Bergeron, C., Rajput, A., Dozic, S., Mastrogiacomo, F., Chang, L., Wilson, J. M., DiStefano, L. M., & Nobrega, J. N. (1992) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1992.tb09439.x · Cited by 537 · cited 1×
“In AD patients, mitochondria isolated from the temporal pole, hippocampus and platelets showed a reduced mitochondrial complex IV activity (Mutisya et al., 1994; Kish et al., 1992).”
BackgroundSelective targeting of an antioxidant to mitochondria
Smith, R. A. J., Porteous, C. M., Coulter, C. V., & Murphy, M. P. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00543.x · Cited by 466 · cited 1×
“There is no obvious toxic effect of MitoVit E on mitochondrial membrane potential and respiration function in vitro at a concentration of 10 μM (Smith et al., 1999).”
BackgroundHaas, R. H., Nasirian, F., Nakano, K., Ward, D., Pay, M., Hill, R., & Shults, C. W. (1995) · Annals of Neurology · doi:10.1002/ana.410370604 · Cited by 435
Antioxidant Vitamin Intake and Risk of Alzheimer Disease
Luchsinger, J. A., Tang, M.-X., Shea, S., & Mayeux, R. (2003) · Archives of Neurology · doi:10.1001/archneur.60.2.203 · Cited by 414 · cited 1×
“Several other independent studies also showed that the administration of Vit E or Vit C alone or in combination failed to demonstrate any benefits for the progression or risk of AD and PD (Luchsinger et al., 2003; McIntosh et al., 1997; Etminan et al., 2005; Weber and Ernst, 2006).”
ResultTherapeutic Effects of Coenzyme Q10and Remacemide in Transgenic Mouse Models of Huntington's Disease
Ferrante, R. J., Andreassen, O. A., Dedeoglu, A., Ferrante, K. L., Jenkins, B. G., Hersch, S. M., & Beal, M. F. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01592.2002 · Cited by 391 · cited 1×
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript Ferrante et al., 2002, 2005; Shults et al., 2004).”
BackgroundGeneration of superoxide by the mitochondrial Complex I
Grivennikova, V. G., & Vinogradov, A. D. (2006) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2006.03.013 · Cited by 379
Graham, D., Huynh, N. N., Hamilton, C. A., Beattie, E., Smith, R. A. J., Cochemé, H. M., Murphy, M. P., & Dominiczak, A. F. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.130351 · Cited by 367
Oxidative stress in Alzheimer's disease brain: New insights from redox proteomics
Butterfield, D. A., Perluigi, M., & Sultana, R. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.06.026 · Cited by 363
Jauslin, M. L., Meier, T., Smith, R. A. J., & Murphy, P. M. (2003) · The FASEB Journal · doi:10.1096/fj.03-0240fje · Cited by 358 · cited 4×
“…and many other neurodegenerative diseases suggest the benefit of mitochondrial protection for attenuation neuronal degeneration (Faust et al., 2009; Fontaine et al., 2000; Jauslin et al., 2003; Kasparova et al., 2006; Liu and Ames, 2005; Du et al., 2008; Cleren et al., 2008; Martin et al., 2009).”
BackgroundInfluentialWang, X., Su, B., Fujioka, H., & Zhu, X. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.071208 · Cited by 341
Cell-permeable, mitochondrial-targeted, peptide antioxidants
Szeto, H. H. (2006) · The AAPS Journal · doi:10.1007/bf02854898 · Cited by 316 · cited 3×
“Its ability to efficiently scavenge free radicals, its water solubility and high blood–brain barrier permeability make these peptides pharmaceutically applicable for neurological diseases (Szeto, 2006).”
BackgroundOxidative and nitrosative stress in Parkinson's disease
Tsang, A. H. K., & Chung, K. K. K. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.12.006 · Cited by 300 · cited 1×
“Massive oxidative stress is also seen in dopaminergic neurons in PD, substantia nigra and cerebellum of PSP, striatum of HD and disease insulted brain regions of many other neurodegenerative diseases (Tsang and Chung, 2009; Tasset et al., 2009; Albers et al., 2000; Aoyama et al., 2006).”
BackgroundMitochondrial Approaches for Neuroprotection
Chaturvedi, R. K., & Beal, M. F. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.027 · Cited by 294 · cited 1×
“CoQ10 has been shown to protect neurons from oxidative stress and severe mitochondrial dysfunction in affected regions of experimental models of PD, epilepsy and stroke (Beal, 2003; Horvath et al., 2003; Chaturvedi and Beal, 2008).”
BackgroundRAGE-mediated signaling contributes to intraneuronal transport of amyloid-β and neuronal dysfunction
Takuma, K., Fang, F., Zhang, W., Yan, S., Fukuzaki, E., Du, H., Sosunov, A., McKhann, G., Funatsu, Y., Nakamichi, N., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905686106 · Cited by 290 · cited 1×
“Damaged complex IV activity also occurred in AD animal models, AD cybrid cells and Aβ-treated cells (Trimmer et al., 2004; Cardoso et al., 2004; Caspersen et al., 2005; Du et al., 2008; Takuma et al., 2005, 2009; Lustbader et al., 2004).”
BackgroundSelf-citationJames, A. M., Sharpley, M. S., Manas, A.-R. B., Frerman, F. E., Hirst, J., Smith, R. A. J., & Murphy, M. P. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611463200 · Cited by 262
Beal, M. F., Matthews, R. T., Tieleman, A., & Shults, C. W. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01192-x · Cited by 256 · cited 2×
“Administration of CoQ10 to aged mice rescued striatal dopamine loss and dopaminergic axonal damage (Beal et al., 1998).”
BackgroundSheehan, J. P., Swerdlow, R. H., Miller, S. W., Davis, R. E., Parks, J. K., Parker, W. D., & Tuttle, J. B. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-12-04612.1997 · Cited by 249
Dhanasekaran, A., Kotamraju, S., Kalivendi, S. V., Matsunaga, T., Shang, T., Keszler, A., Joseph, J., & Kalyanaraman, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404003200 · Cited by 241
Bioenergetic approaches for neuroprotection in Parkinson's disease
Beal, M. F. (2003) · Annals of Neurology · doi:10.1002/ana.10479 · Cited by 236 · cited 1×
“CoQ10 has been shown to protect neurons from oxidative stress and severe mitochondrial dysfunction in affected regions of experimental models of PD, epilepsy and stroke (Beal, 2003; Horvath et al., 2003; Chaturvedi and Beal, 2008).”
BackgroundMitochondrial Medicine for Aging and Neurodegenerative Diseases
Reddy, P. H. (2008) · NeuroMolecular Medicine · doi:10.1007/s12017-008-8044-z · Cited by 230 · cited 3×
“Cell toxicity lessened at concentrations up to 10 μM of MitoQ, though there was a report that MitoQ damaged N2a cells at concentrations higher than 0.3 μM (Reddy, 2008).”
BackgroundInfluentialPilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease
Shults, C. W., Flint Beal, M., Song, D., & Fontaine, D. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.05.003 · Cited by 223 · cited 1×
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript Ferrante et al., 2002, 2005; Shults et al., 2004).”
BackgroundRodriguez-Cuenca, S., Cochemé, H. M., Logan, A., Abakumova, I., Prime, T. A., Rose, C., Vidal-Puig, A., Smith, A. C., Rubinsztein, D. C., Fearnley, I. M., et al. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.10.039 · Cited by 218
A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease
Fahn, S. (1992) · Annals of Neurology · doi:10.1002/ana.410320722 · Cited by 211 · cited 1×
“The combination of Vit E and Vit C has been reported to delay the progression of PD (Fahn, 1992; Fahn and Cohen, 1992).”
BackgroundMitochondria and Huntington's Disease Pathogenesis: Insight from Genetic and Chemical Models
Browne, S. E. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.018 · Cited by 176
Petri, S., Kiaei, M., Damiano, M., Hiller, A., Wille, E., Manfredi, G., Calingasan, N. Y., Szeto, H. H., & Beal, M. F. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04018.x · Cited by 166
Conte, V., Uryu, K., Fujimoto, S., Yao, Y., Rokach, J., Longhi, L., Trojanowski, J. Q., Lee, V. M., McIntosh, T. K., & Praticò, D. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02560.x · Cited by 164 · cited 1×
“Four weeks of Vit E supplementation in an AD mouse model (Tg2576 mice at 11 months old) improved mice cognitive function and reduced the Aβ deposition (Conte et al., 2004).”
MethodGutzmann, H., & Hadler, D. (1998) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-7508-8_30 · Cited by 162 · cited 1×
“CoQ10 treatment significantly ameliorates cognitive impairment (Senin et al., 1992; Gutzmann and Hadler, 1998).”
Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment
Valla, J., Schneider, L., Niedzielko, T., Coon, K. D., Caselli, R., Sabbagh, M. N., Ahern, G. L., Baxter, L., Alexander, G., Walker, D. G., et al. (2006) · Mitochondrion · doi:10.1016/j.mito.2006.10.004 · Cited by 159 · cited 1×
“Reduced complex III activity has also been detected in mitochondria isolated from affected brain regions as well as platelets of AD and Down’s syndrome patients (Kim et al., 2000; Valla et al., 2006).”
BackgroundTolerance of high‐dose (3,000 mg/day) coenzyme Q10 in ALS
Ferrante, K. L., Shefner, J., Zhang, H., Betensky, R., O'Brien, M., Yu, H., Fantasia, M., Taft, J., Beal, M. F., Traynor, B., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187070.35365.d7 · Cited by 154
Potent mitochondria-targeted peptides reduce myocardial infarction in rats
Cho, J., Won, K., Wu, D., Soong, Y., Liu, S., Szeto, H. H., & Hong, M. K. (2007) · Coronary Artery Disease · doi:10.1097/01.mca.0000236285.71683.b6 · Cited by 144
Protection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson's disease
Marella, M., Seo, B. B., Nakamaru-Ogiso, E., Greenamyre, J. T., Matsuno-Yagi, A., & Yagi, T. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001433 · Cited by 116 · cited 1×
“By incorporating NDI1 into mitochondria, a group revealed that the expression of NDI1 restores the NADH dehydrogenase activity and as a result, protects neurons in the substantia nigra of a Parkinson’s disease rat model from severe degeneration (Marella et al., 2008).”
BackgroundYang, X., Yang, Y., Li, G., Wang, J., & Yang, E. S. (2008) · Journal of Molecular Neuroscience · doi:10.1007/s12031-007-9033-7 · Cited by 111 · cited 3×
“Deficiency in PINK1 causes decreased mitochondrial cristae and elongated large mitochondria (Yang et al., 2008c).”
BackgroundIdebenone in senile dementia of Alzheimer type: A multicentre study
Senin, U., Parnetti, L., Barbagallo-Sangiorgi, G., Bartorelli, L., Bocola, V., Capurso, A., Cuzzupoli, M., Denaro, M., Marigliano, V., Tammaro, A. E., et al. (1992) · Archives of Gerontology and Geriatrics · doi:10.1016/0167-4943(92)90060-h · Cited by 72
Cited by
Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model
Du, H., Guo, L., Yan, S., Sosunov, A. A., McKhann, G. M., & ShiDu Yan, S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006586107 · Cited by 704
Self-citationMitochondrial permeability transition pore is a potential drug target for neurodegeneration
Rao, V. K., Carlson, E. A., & Yan, S. S. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.003 · Cited by 324
Self-citationMitochondrial Dysfunction and Synaptic Transmission Failure in Alzheimer’s Disease
Guo, L., Tian, J., & Du, H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160702 · Cited by 211
Self-citationYan, L., Guo, M.-S., Zhang, Y., Yu, L., Wu, J.-M., Tang, Y., Ai, W., Zhu, F.-D., Law, B. Y.-K., Chen, Q., et al. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5288698 · Cited by 97
The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics
Pritchard, S. M., Dolan, P. J., Vitkus, A., & Johnson, G. V. W. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01273.x · Cited by 89
“Indeed, mitochondria have been increasingly recognized as a beneficial therapeutic target in neurodegenerative diseases, including AD [166].”
Background
Metadata
- Authors
- Du, H., & Yan, S. S.
- Venue
- The International Journal of Biochemistry & Cell Biology
- Publisher
- Elsevier BV
- Published
- 2010-05
- Volume
- 42
- Issue
- 5
- Pages
- 560-572
- ISSN
- 1357-2725 (ISSN-L)
- OpenAlex
- W2149562999
- Cited by
- 81
- References
- 58
- FWCI
- 2.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.